Hemp Industries Ass'n v. Drug Enforcement Admin.

Citation333 F.3d 1082
Decision Date30 June 2003
Docket NumberNo. 01-71662.,01-71662.
PartiesHEMP INDUSTRIES ASSOCIATION; Nutiva, Inc.; Tierra Madre, LLC; Hemp Oil Canada, Inc.; North Farm Cooperative; Kenex Ltd.; Nature's Path Foods USA Inc.; Hempola, Inc., Petitioners, v. DRUG ENFORCEMENT ADMINISTRATION; The Honorable Asa Hutchinson, Administrator, Respondents.
CourtUnited States Courts of Appeals. United States Court of Appeals (9th Circuit)

Patrick Goggin, Sandler, Reiff & Young, P.C., San Francisco, CA, for the appellants-petitioners.

Joseph E. Sandler, Sandler, Reiff & Young, P.C., Washington, D.C., for the appellants-petitioners.

Daniel Dormont, Drug Enforcement Agency, Alexandria, VA, for the appellees-respondents.

On Petition for Review of an Order of the Drug Enforcement Agency.

Before SCHROEDER, Chief Judge, B. FLETCHER and KOZINSKI, Circuit Judges.

Opinion by Judge BETTY B. FLETCHER; Dissent by Judge KOZINSKI.

OPINION

BETTY B. FLETCHER, Circuit Judge:

INTRODUCTION

Petitioners challenge the validity of the rule issued by the respondent that bans the sale of consumable products containing hemp oil, cake, or seed. They contend that the rule is a legislative rule that is subject to the notice and comment procedure required by the Administrative Procedures Act (APA). Respondent contends that the rule is an interpretive rule,1 and need not undergo such procedures. We hold that because the rule would force plaintiffs either to risk sanction or to forego the theretofore legal activity of selling products containing trace amounts of naturally occurring THC, it is a legislative rule, and should have been subjected to notice and comment procedures.

I. JURISDICTION

As a threshold matter, we must ask whether we have jurisdiction to hear this case under the administrative appeal provision of the Controlled Substances Act, 21 U.S.C. § 877 ("CSA"). This section provides that:

All final determinations, findings, and conclusions of the Attorney General under this title shall be final and conclusive decisions of the matters involved, except that any person aggrieved by a final decision of the Attorney General may obtain review of the decision in the United States Court of Appeals for the District of Columbia or for the circuit in which his principal place of business is located upon petition filed with the court and delivered to the Attorney General within thirty days after notice of the decision. Findings of fact by the Attorney General, if supported by substantial evidence, shall be conclusive.

The rule under challenge was published on October 9, 2001. 66 Fed.Reg. 51530. Petitioners filed a timely petition for review on October 19. The question of whether we have jurisdiction thus depends on whether this is a final determination of the Attorney General. Petitioners, arguing that the rule is a final determination, urge this court to accept jurisdiction. Respondent agrees that, although there is no precedent as to whether an interpretive rule is final within the meaning of § 877, this court has jurisdiction.

Since we conclude that the rule is legislative, in that it is final agency action imposing obligations and sanctions in the event of violation, we have jurisdiction on the facts of this case. We need not decide whether we would have original jurisdiction over an interpretive rule or whether our assumption of jurisdiction would oust district court jurisdiction under the APA.

II. FACTUAL AND PROCEDURAL BACKGROUND

The petitioners describe themselves as companies that manufacture, distribute, and/or sell processed hemp seed or oil, or food and beverages that contain nutritionally-valuable hemp seed or oil in the United States. Since 1937, the statute controlling marijuana has excluded the oil and sterilized seed of the plant Cannabis sativa L., commonly known as hemp, from the definition of marijuana. 21 U.S.C. § 802(16). Relying on this exemption, U.S. individuals and businesses, including the petitioners, have purchased and sold consumable products containing sterilized hemp seeds and oil, which generally are imported from Canada or Europe.2

Tetrahydrocannabinols ("THC") is the active ingredient in marijuana. Hemp seeds and oil typically contain minuscule trace amounts of THC, less than 2 parts per million in the seed and 5 parts per million in the oil. Enhanced analytical testing indicates that "a `THC Free' status is not achievable in terms of a true zero." Petitioner's Reply on Emergency Motion for Stay, Exh. 2 Crew Dec. at 2. Nonetheless, the amount of trace THC present in hemp seed and oil is sufficiently low to prevent confirmed positives in urine drug-testing for marijuana even from extended and extensive consumption of hemp foods. Leson, Pless, Grotenhermen, Kalant and ElSohly, "Evaluating the Impact of Hemp Food Consumption on Workplace Drug Tests," 25 Journal of Analytical Toxicology 691 (Nov./Dec.2001).

On October 9, 2001, the DEA issued three rules. The first is what the DEA denominates an "Interpretive Rule," purporting to interpret both the CSA and the DEA regulations to ban all naturally-occurring THC, including that found in hemp seed and oil, on Schedule I. 66 Fed. Reg. 51,530 (October 9, 2001). The DEA did not provide notice or solicit comments with regard to this rule. The second is an "Interim Rule," exempting industrial hemp products not intended for human consumption from the application of the CSA and providing a 120-day grace period for persons to dispose of existing inventories of consumable products containing naturally occurring THC. 66 Fed.Reg. 51,539 (October 9, 2001). The third rule is a proposed amendment to the DEA regulations to add natural THC to the listing of THC in Schedule I. 66 Fed.Reg. 51,535 (October 9, 2001).3

The petitioners bring this appeal to challenge the putative interpretive rule, arguing that it is in reality an invalid legislative rule that was promulgated without observance of the procedures required by the APA.4

III. DISCUSSION
A. Standard of review

Whether an agency rule is interpretive or legislative is a question of law reviewed de novo. Chief Probation Officers of Cal. v. Shalala, 118 F.3d 1327 (9th Cir.1997).

B. Standing

The DEA argues that the petitioners lack standing to challenge the putative interpretive rule. To establish standing, the petitioners must demonstrate three elements:

First, plaintiffs must clearly demonstrate that they have suffered an "injury in fact" — an invasion of a legally protected interest which is (a) concrete and particularized, and (b) actual or imminent, not conjectural or hypothetical. Second, there must be a causal connection between the injury and the conduct complained of — the injury has to be fairly traceable to the challenged action of the defendant. Third, it must be likely, as opposed to merely speculative, that the injury will be redressed by a favorable decision.

Lujan v. Defenders of Wildlife, 504 U.S. 555, 559, 112 S.Ct. 2130, 119 L.Ed.2d 351 (1992). The DEA claims that the petitioners cannot demonstrate an injury in fact because they have not shown that the DEA or any other agency has seized their products or commenced criminal proceedings against them as a result of the putative interpretive rule. This fact does not prevent them from having standing.

In City of Auburn v. Qwest, 260 F.3d 1160, 1171 (9th Cir.2001), this court observed that, "[i]f [p]romulgation of the challenged regulations present[s] plaintiffs with the immediate dilemma to choose between complying with newly imposed, disadvantageous restrictions and risking serious penalties for violation, the controversy is ripe." Because standing overlaps substantially with ripeness with respect to the promulgation of new regulations, there is also standing in these circumstances. Id. at 1172 n. 6. (citation and internal quotation marks omitted). The petitioners meet this test. If the rule stands, the petitioners must either stop manufacturing, distributing, and selling in the United States hemp seed and oil products or face criminal penalties for violating the DEA's restrictions on Schedule I substances.

The DEA emphasizes that petitioners state only that their products "may" contain THC rather than affirmatively stating that they do contain THC. But the petitioners have presented evidence that a true zero level of THC in hemp seed and oil is not achievable. Thus, because the DEA has failed to indicate any limit of detectable amounts for THC, the manufacture, distribution, and sale of hemp seed and oil products, which inevitably contain some trace THC, could prompt enforcement actions by the DEA. For this reason, petitioners have standing.

C. The validity of the DEA's rule
1. Legal framework

An agency can issue a legislative rule only by using the notice and comment procedure described in the APA, unless it publishes a specific finding of good cause documenting why such procedures "are impracticable, unnecessary, or contrary to the public interest." 5 U.S.C. § 553(b), (b)(B). In contrast, an agency need not follow the notice and comment procedure to issue an interpretive rule. § 553(b)(A). The distinction between the two procedures is key in this case. If the DEA's rule is genuinely an interpretive rule, it is valid despite the absence of notice and comment procedures. If the DEA's rule has the effect of a legislative rule, it is invalid because of the agency's failure to comply with the APA procedures.

While the DEA has characterized its rule as an interpretive rule, the court need not accept the agency characterization at face value. See Gunderson v. Hood, 268 F.3d 1149, 1154 n. 27 (9th Cir. 2001); Richard L. Pierce, Jr., Distinguishing Legislative Rules From Interpretive Rules, 52 Admin. L.Rev. 547, 555 (2000).

Courts have struggled with identifying the difference between legislative rules and interpretive rules. In general terms, interpretive rules merely explain, but do not add to, the substantive law that already exists in the form...

To continue reading

Request your trial
67 cases
  • Texas Department of State Health Services v. Crown Distributing LLC
    • United States
    • Supreme Court of Texas
    • June 24, 2022
    ...HEALTH & SAFETY CODE § 481.002(26).63 These excluded parts and products were "commonly known as hemp," Hemp Indus. Ass'n v. Drug Enf't Admin. , 333 F.3d 1082, 1085 (9th Cir. 2003), although the statutes did not refer to them by that name.Congress began to change the legal landscape by passi......
  • US Citrus Sci. Council v. U.S. Dep't of Agric.
    • United States
    • U.S. District Court — Eastern District of California
    • February 27, 2018
    ...the force of law, it may still be legislative if it is inconsistent with a prior rule having the force of law. Hemp Indus. Ass'n v. DEA , 333 F.3d 1082, 1087 (9th Cir. 2003). The OWP does not fit neatly within either category described in Hemp Industries : the OWP is more than an explanatio......
  • Inst. for Fisheries Res. v. Hahn
    • United States
    • U.S. District Court — Northern District of California
    • December 19, 2019
    ...legislative basis to consider new-animal-drug applications related to genetically engineered animals. Cf. Hemp Industries Association v. DEA , 333 F.3d 1082, 1090 (9th Cir. 2003).4 Second, the FDA disavowed resort to its legislative authority to issue the guidance document. AR 571. And thir......
  • Advanced Integrative Med. Sci. Inst., PLLC v. Garland
    • United States
    • United States Courts of Appeals. United States Court of Appeals (9th Circuit)
    • January 31, 2022
    ...applied Bennett in interpreting "final decision" in § 877, we have applied similar reasoning in that context. See Hemp Indus. Ass'n v. DEA , 333 F.3d 1082, 1085 (9th Cir. 2003). In Hemp , the DEA published a rule that banned the sale of certain products containing hemp products in the Feder......
  • Request a trial to view additional results
4 books & journal articles
  • Administering the National Environmental Policy Act
    • United States
    • Environmental Law Reporter No. 45-4, April 2015
    • April 1, 2015
    ...Common Sense in Gov’t Procurement v. Secretary of Veterans Afairs, 464 F.3d 1306, 1317-18 (Fed. Cir. 2006); Hemp Industries Ass’n v. DEA, 333 F.3d 1082, 1087-91 (9th Cir. 2003); Shell Ofshore. Inc. v. Babbitt, 238 F.3d 622, 627-30 (5th Cir. 2001); Caruso v. Blockbuster-Sony Music Entm’t Ctr......
  • §12.2 Enforcement and Regulation of Cannabis-Derived Ingestible Products
    • United States
    • Full Court Press DeWitty on Dietary Supplement Law Title CHAPTER 12 Cannabis-Derived Products as Dietary Supplements
    • Invalid date
    ...that possession and manufacture of IHM and WHM be permitted.").[56] See, Hemp Industries Ass'n v. Drug Enforcement Administration, 333 F.3d 1082 (9th Cir. 2003); see also, Hemp Industries Ass'n v. Drug Enforcement Administration, 357 F.3d 1012 (9th Cir. 2004); Hemp Industries Ass'n v. Drug ......
  • All Rise! Standing in Judge Betty Fletcher's Court
    • United States
    • University of Washington School of Law University of Washington Law Review No. 85-1, September 2015
    • Invalid date
    ...S. Ct. 2824 (2009). 23. 42 U.S.C. §§ 12101-12213 (2006). 24. D'Lil, 518 F.3d at 1037-80. 25. Id. at 1041-43 (Rymer, J., dissenting). 26. 333 F.3d 1082 (9th Cir. 27. Id. at 1085 n.3 (mootness), 1086-87 (standing). 28. Id. 29. Id. at 1091. 30. Id. at 1092 (Kozinski, J., dissenting). 31. 206 F......
  • Table of Cases
    • United States
    • Full Court Press DeWitty on Dietary Supplement Law Title Table of Cases
    • Invalid date
    ...§1.6 Hemp Indus. Ass'n v. U.S. Drug Enforcement Admin, 20-2921 (JEB), §12.2.3.2 Hemp Industries Ass'n v. Drug Enforcement Administration, 333 F.3d 1082 (9th Cir. 2003), §12.2.3.2 Hipolite Egg Co. v. United States - 220 U.S. 45, 31 S. Ct. 364 (1911) A, §2.2 Horn v. Medical Marijuana, Inc., 3......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT